Session IX: Hepatocellular Cancer

Chair(s)

• 

  Thomas Gruenberger, MD

  Clinic Favoriten, Dept Surgery, HPB Center, health network Vienna
  Vienna, Austria
• 

  Michel Ducreux, MD, PhD

  Gustave Roussy
  Paris, France

Presentations:

• 14:50 – 15:10

  Pathogenesis and Subtypes of HCC
  

  Speaker: Josep M. Llovet, MD, PhD – Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS) / ICAHN School of Medicine at Mount Sinai
• 15:10 – 15:30

  Diagnostic and Imaging Challenges in HCC
  

  Speaker: Vincent Vandecaveye, MD, PhD – University Hospitals Leuven - KU Leuven
• 15:30 – 15:42

  O-5: Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study
  

  Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
• 15:42 – 15:50

  SO-12: Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
  

  Abstract Presenter: Ignacio Melero
• 15:50 – 15:58

  SO-13: Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the open-label, phase 2 KEYNOTE-224 study
  

  Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
• 15:58 – 16:06

  SO-14: Atezolizumab Plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
  

  Abstract Presenter: Andrea Casadei-Gardini
• 16:06 – 16:14

  SO-15: Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma
  

  Abstract Presenter: Firas Baidoun
• 16:14 – 16:30

  Discussant: O-5, SO-12, SO-13, SO-14, SO-15
  

  Discussant: Peter R. Galle, MD, PhD – Universitätsmedizin Mainz
• 16:30 – 17:15

  Cases With Panel Discussion: Management Strategy in HCC
  

  Panelist: Josep M. Llovet, MD, PhD – Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS) / ICAHN School of Medicine at Mount Sinai

  Panelist: Chris J. Verslype, MD PhD – University Hospital Gasthuisberg

  Panelist: Arndt Vogel, MD – Medizinische Hochschule Hannover

  Panelist: Bruno Sangro, MD, PhD – Clinica Universidad de Navarra

  Panelist: René André Adam, MD, PhD – Paul Brousse Hospital

  Panelist: Thierry de Baere, MD – Institut Gustave Roussy

  Moderator: Michel P. Ducreux, MD, PhD – Gustave Roussy

  Moderator: Thomas Gruenberger, MD – Clinic Favoriten, Dept Surgery, HPB Center, health network Vienna
• 17:45 – 18:05

  How to Integrate and Sequence New Agents in HCC?
  

  Speaker: Bruno Sangro, MD, PhD – Clinica Universidad de Navarra
• 18:05 – 18:25

  Challenges and Indications for Locoregional Treatment in HCC
  

  Speaker: Thierry de Baere, MD – Institut Gustave Roussy
• 18:25 – 18:35

  Q&A and Panel Discussion
  

  Moderator: Thomas Gruenberger, MD – Clinic Favoriten, Dept Surgery, HPB Center, health network Vienna

  Moderator: Michel P. Ducreux, MD, PhD – Gustave Roussy

  Panelist: Thierry de Baere, MD – Institut Gustave Roussy

  Panelist: Bruno Sangro, MD, PhD – Clinica Universidad de Navarra